Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11
Licensing Agreements 12
Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14
Equity Offering 15
Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15
Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16
Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18
Rigel Pharma Raises USD46 Million in Public Offering of Shares 19
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 22
Rigel Pharmaceuticals Inc – Key Competitors 24
Rigel Pharmaceuticals Inc – Key Employees 25
Rigel Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 08, 2018: Rigel Pharmaceutical reports second quarter 2018 financial results 27
May 01, 2018: Rigel Reports First Quarter 2018 Financial Results 28
Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update 30
Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update 32
Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 33
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 34
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 36
Corporate Communications 38
Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer 38
Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors 39
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 40
Product News 41
04/17/2018: Rigel Announces FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients 41
04/12/2018: Rigel Makes Statement Regarding Website Error 42
01/30/2017: Fostamatinib Study Results Continue to Trend Positive 43
Product Approvals 44
Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 44
Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 45
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 46
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 47
Clinical Trials 48
Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases 48
Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo 49
Apr 03, 2018: Rigel Announces Topline Data From Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy 50
Mar 01, 2018: Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America 51
Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference 52
Dec 08, 2017: Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting 54
Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 55
Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11
Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14
Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15
Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16
Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18
Rigel Pharma Raises USD46 Million in Public Offering of Shares 19
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 22
Rigel Pharmaceuticals Inc, Key Competitors 24
Rigel Pharmaceuticals Inc, Key Employees 25
List of Figures
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9